1. Home
  2. Analysis

Paraesthesia and drugs of ingredients of everolimus (a real world drug study)


Summary:

Paraesthesia is found among people who take drugs with ingredients of everolimus, especially for people who are female, 60+ old , have been taking the drugs for 1 - 6 months. This phase IV clinical study is created by eHealthMe based on reports of 59,204 people who have side effects when taking drugs with ingredients of everolimus from the FDA, and is updated regularly.

Drug(s) considered in the study (i.e. both brand name and generic drugs): Afinitor, Afinitor disperz, Everolimus, Rad001, Zortress.

On Nov, 28, 2025

59,204 people reported to have side effects when taking drugs with ingredients of everolimus.
Among them, 372 people (0.63%) have Paraesthesia

What is Paraesthesia?

Paraesthesia (sensation of tingling, tickling, prickling, pricking, or burning of a person's skin with no apparent long-term physical effect) is found to be associated with 2,709 drugs and 3,105 conditions by eHealthMe. Check the latest studies of Paraesthesia.

Number of reports submitted per year:

Could drugs with ingredients of everolimus cause Paraesthesia?

Time on drugs with ingredients of everolimus when people have Paraesthesia *:

  • < 1 month: 28.36 %
  • 1 - 6 months: 41.79 %
  • 6 - 12 months: 26.87 %
  • 1 - 2 years: 2.99 %
  • 2 - 5 years: 0.0 %
  • 5 - 10 years: 0.0 %
  • 10+ years: 0.0 %

Gender of people who have Paraesthesia when taking drugs with ingredients of everolimus *:

  • female: 81.06 %
  • male: 18.94 %

Age of people who have Paraesthesia when taking drugs with ingredients of everolimus *:

  • 0-1: 0.0 %
  • 2-9: 0.0 %
  • 10-19: 2.06 %
  • 20-29: 0.6900000000000001 %
  • 30-39: 7.9 %
  • 40-49: 18.56 %
  • 50-59: 32.65 %
  • 60+: 38.14 %

Conditions people have *:

You may use this to check any potential undetected conditions.

  1. Breast Cancer Stage Ii: 55 people, 14.78%
  2. Metastases To Liver (cancer spreads to liver): 52 people, 13.98%
  3. Metastases To Bone (cancer spreads to bone): 46 people, 12.37%
  4. Pain: 36 people, 9.68%
  5. Renal Cell Carcinoma (a kidney cancer): 34 people, 9.14%
  6. Pancreatic Neuroendocrine Tumor: 29 people, 7.80%
  7. Metastatic Bronchial Carcinoma (spread of cancer to bronchi tumour): 24 people, 6.45%
  8. Neuroendocrine Tumor: 20 people, 5.38%
  9. Depression: 16 people, 4.30%
  10. Inflammatory Pain: 16 people, 4.30%

Other drugs people take *:

You may use this to check any potential interacting drugs.

  1. Taxotere: 57 people, 15.32%
  2. Rivaroxaban: 53 people, 14.25%
  3. Zometa: 51 people, 13.71%
  4. Magnesium: 51 people, 13.71%
  5. Xeloda: 47 people, 12.63%
  6. Taxol: 46 people, 12.37%
  7. Faslodex: 45 people, 12.10%
  8. Sandostatin: 26 people, 6.99%
  9. Letrozole: 23 people, 6.18%
  10. Exemestane: 22 people, 5.91%

Other side effects people have besides Paraesthesia *:

You may use this to check any potential undetected side effects.

  1. Nausea (feeling of having an urge to vomit): 189 people, 50.81%
  2. Fatigue (feeling of tiredness): 150 people, 40.32%
  3. Chest Pain: 149 people, 40.05%
  4. Diarrhea: 148 people, 39.78%
  5. Rashes (redness): 139 people, 37.37%
  6. Nausea And Vomiting: 122 people, 32.80%
  7. Drug Ineffective: 120 people, 32.26%
  8. Headache (pain in head): 112 people, 30.11%
  9. Weakness: 110 people, 29.57%
  10. Metastases To Bone (cancer spreads to bone): 106 people, 28.49%

* Approximation only. Some reports may have incomplete information.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Related studies

Drugs with ingredients of everolimus, their effectiveness, alternatives and more:

How the study uses the data?

The study uses data from the FDA. It is based on everolimus. All drugs that have the same active ingredients (e.g. brand name and generic drugs) are considered. Dosage of drugs is not considered in the study.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.

Recent studies on eHealthMe:

© 2025 eHealthMe.com. All rights reserved. Use of this site constitutes acceptance of eHealthMe.com's terms of service and privacy policy.